Methods for treating Covid-19
AssigneeMedstar Health, Inc.
InventorsThomas M. Fishbein, Khalid M. Khan, Alexander H. Kroemer
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for treating COVID-19 by targeting the inflammasome/caspase1/pyroptosis axis as a key inflammatory pathway. In particular, the invention relates to treating a patient infected with SARS-CoV-2 with an effective amount of one or more compounds that directly or indirectly inhibit one or more pathways of the inflammasome/caspase1/pyroptosis axis.
Claims37
A method for treating a patient infected with SARS-CoV-2 or a variant thereof, wherein the SARS-CoV-2 and the variant thereof have pyroptotic activity, said method comprising
- (a) determining if the patient is infected with SARS-CoV-2 or the variant thereof,
- (b) optionally determining if the patient has pyroptotic activity or a comorbidity associated with upregulation of an inflammasome/caspase/pyroptosis axis, and
- (c) administering to the patient infected with SARS-CoV-2 or a variant thereof an effective amount of about 10 mg/kg to about 100 mg/kg of a compound having the formula
- or a derivative, or a prodrug of the compound,
- wherein the administering comprises administering a composition comprising the effective amount of the compound, or the derivative of the compound, or the prodrug of the compound and a pharmaceutically acceptable carrier.
A method for treating a patient infected with SARS-CoV-2 or a variant thereof, wherein the SARS-CoV-2 and the variant thereof have pyroptotic activity, said method comprising
- (a) determining if the patient is infected with SARS-CoV-2 or the variant thereof,
- (b) optionally determining if the patient has pyroptotic activity or a comorbidity associated with upregulation of an inflammasome/caspase/pyroptosis axis, and
- (c) administering to the patient infected with SARS-CoV-2 or a variant thereof an effective amount of about 10 mg/kg to about 100 mg/kg of a compound having the formula
- or a salt of the compound,
- wherein the administering comprises administering a composition comprising the effective amount of the compound, or the salt of the compound and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.